Denise Giuvelis, B.S.
COBRE Behavior Core Manager
I currently manage the COBRE Behavior Core. We offer a wide variety of services for all your behavior testing needs. I began working in a research laboratory at UNE during the summer of 2006 as part of the Federal Work Study program. I was interested in gaining the knowledge and skills required to work in a research environment. Quickly I learned basic pharmacology and behavioral neuroscience techniques and was able to start my own projects with senior members in the laboratory. I graduated cum laude with a B.S. in Medical Biology in December of 2007 and began working full-time as a laboratory manager in June 2007. Since then, I have transitioned into managing the COBRE Behavioral Core. Working in this role allows me to aid in designing and conducting experiments as well as training research staff and undergraduates. Over the past several years I have gathered expertise is in a variety of assays looking at preclinical analgesic efficacy and side effects.
Payne E, Harrington K, Richard P, Brackin R, Davis R, Couture S, Liff J, Asmus F, Mutina E, Fisher A, Giuvelis D, Sannajust S, Rostama B, King T, Mattei LM, Lee JJ, Friedman ES, Bittinger K, May M, Stevenson GW. Effects of Vancomycin on Persistent Pain-Stimulated and Pain-Depressed Behaviors in Female Fischer Rats With or Without Voluntary Access to Running Wheels. J Pain. 2021 May 21:S1526-5900(21)00234-0. doi: 10.1016/j.jpain.2021.05.003.
Beckley JT, Pajouhesh H, Luu G, Klas S, Delwig A, Monteleone D, Zhou X, Giuvelis D, Meng ID, Yeomans DC, Hunter JC, Mulcahy JV. Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain. Pain. 2021 Apr 1;162(4):1250-1261. doi: 10.1097/j.pain.0000000000002112.
Nguyen LD, Nolte LG, Tan WJT, Giuvelis D, Santos-Sacchi J, Bilsky E, Ehrlich BE. Comprehensive somatosensory and neurological phenotyping of NCS1 knockout mice. Sci Rep. 2021 Jan 27;11(1):2372. doi: 10.1038/s41598-021-81650-5.
Stevenson GW, Giuvelis D, Cormier J, Cone K, Atherton P, Krivitsky R, Warner E, St Laurent B, Dutra J, Bidlack JM, Szabò L, Polt R, Bilsky EJ. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration. Psychopharmacology (Berl). 2020 Apr;237(4):1195-1208. doi: 10.1007/s00213-019-05449-z. Epub 2020 Jan 7.
Huynh PN, Giuvelis D, Christensen S, Tucker KL, McIntosh JM. RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats. Mar Drugs. 2019 Dec 21;18(1):12. doi: 10.3390/md18010012.
Warner E, Krivitsky R, Cone K, Atherton P, Pitre T, Lanpher J, Giuvelis D, Bergquist I, King T, Bilsky EJ, Stevenson GW. Evaluation of a postoperative pain-like state on motiviated behavior in rats: Effects of plantar incision on proressive-ratio food-maintained responding. Drug Dev Res. 2015 Dec;76(8):432-41.
Lefever M, Li Y, Anglin B, Muthu D, Giuvelis D, Lowery JJ, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Structural requirements for CNS active opioid glycopeptides. J Med Chem. 2015 Aug 13;58(15):5728-41.
Stevenson GW, Luginbuhl A, Dunbar C, LaVigne J, Dutra J, Atherton P, Bell B, Cone K, Giuvelis D, Polt R, Streicher JM, Bilsky EJ. The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats and induces in vitro markers of tolerance and dependence. Pharmacol Biochem Behav. 2015 May;132:49-55.
Li Y, St Louis L, Knapp BI, Muthu D, Anglin B, Giuvelis D, Bidlack JM, Bilsky EJ, Polt R. Can amphipathic helices influence the CNS antinocicpetive activity of glycopeptides related to B-endorphin? J Med Chem. 2014 Mar27;57(6):2237-46.
Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D,Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW. Building a Better Analgesic: Multifunctional Compounds that Address Injury-Induced Pathology to Enhance Analgesic Efficacy while Eliminating Unwanted Side Effects. J Pharmacol Exp Ther. 2013 Oct;347(1):7-19.
Ananthan S, Saini SK, Dersch CM, Xu H, McGlinchey N, Giuvelis D, Bilsky EJ, Rothman RB. 14-Alkoxy- and 14-acyloxypyridomorphinans: _ agonist/_ antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem. 2012 Oct 11;55(19):8350-63.
Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ. In vivo characterization of MMP-2200, a mixed _/_ opioid agonist, in mice. J Pharmacol Exp Ther. 2011 Mar;336(3):767-78.
Bilsky EJ, Giuvelis D, Osborn MD, Dersch CM, Xu H, Rothman RB. In vitro and in vivo assessment of mu opioid receptor constitutive activity. Methods Enzymol. 2010;484:413-43.
Osborn MD, Lowery JJ, Skorput AG, Giuvelis D, Bilsky EJ. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci. 2010 Apr 10;86(15-16):624-30.
Sally EJ, Xu H, Dersch CM, Hsin LW, Chang LT, Prisinzano TE, Simpson DS, Giuvelis D, Rice KC, Jacobson AE, Cheng K, Bilsky EJ, Rothman RB. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse. 2010 Apr;64(4):280-8.
Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem. 2007 Aug 9;50(16):3765-76.